Sermorelin / GHRP-6 Blend
Also known as: Sermorelin & GHRP-6, Sermorelin + GHRP-6 Blend
A research blend combining the GHRH analog Sermorelin with the ghrelin-receptor agonist GHRP-6. It is studied for synergistic growth hormone release and appetite stimulation.
Last updated
Mechanism of Action
Sermorelin (GHRH 1-29) activates the pituitary GHRH receptor to drive growth hormone synthesis and release. GHRP-6 is a hexapeptide agonist of the GHS-R1a (ghrelin) receptor that evokes a separate GH pulse, reduces somatostatin inhibition, and strongly stimulates appetite. The two compounds engage distinct receptor pathways, producing a synergistic amplification of pulsatile GH secretion while maintaining physiologic feedback control.
- Half-life
- Mixed: Sermorelin ~10-20 minutes, GHRP-6 ~15-60 minutes
- Administration Routes
- subcutaneous
- Research Status
- Research Chemical
Reported Benefits
- Studied for synergistic endogenous GH release
- Investigated for appetite stimulation in research models
- Examined for improved recovery and lean mass support
- Researched for enhanced sleep depth and quality
- Studied for IGF-1 elevation through natural pituitary signaling
Potential Side Effects
- Marked increase in hunger from GHRP-6 activity
- Injection-site redness or transient swelling
- Transient flushing or warmth after injection
- Water retention or tingling in extremities
- Possible mild elevation of cortisol and prolactin
Common Dosing
In the research literature, blends are studied at roughly 100-300 mcg of each component per administration, 1-3 times daily, often pre-sleep or fasted. For research-use only; not personal medical advice.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Active malignancy or history of cancer
- Pregnancy or breastfeeding
- Known hypersensitivity to GHRH or GHRP analogs
Sermorelin / GHRP-2 Blend
A research blend pairing the GHRH analog Sermorelin with the growth hormone-releasing peptide GHRP-2. The combination is studied for synergistic stimulation of endogenous growth hormone.
Sermorelin / Ipamorelin Blend
A widely studied research blend combining the GHRH analog Sermorelin with the highly selective ghrelin-receptor agonist Ipamorelin. It is examined for clean, synergistic growth hormone release with minimal off-target effects.
CJC-1295 (No DAC) / GHRP-6 Blend
This blend combines CJC-1295 without DAC (Mod GRF 1-29), a GHRH analog, with GHRP-6, a ghrelin-mimetic secretagogue noted for strong appetite stimulation, to synergistically boost growth hormone release. Both are unapproved research peptides.
- View
Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency
1999
- View
Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone
1990
- View
Growth hormone secretion after the administration of GHRP-6 or GHRH combined with GHRP-6 does not decline in late adulthood
1995
- View
The GHRH/GHRP-6 test for the diagnosis of GH deficiency in elderly or severely obese men
2005
- View
Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?
2006